Hangzhou Hanx Biopharmaceuticals
Hangzhou Hanx Biopharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HX009 in glioma & glioblastoma, biliary tract cancer and melanoma.
Overview
Hangzhou Hanx Biopharmaceuticals, based in Wuhan, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HX009 in glioma & glioblastoma, biliary tract cancer and melanoma. The largest, NCT06708663 (HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours), plans to enrol 124 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyPhilogen S.p.A.
Shares Glioma & glioblastoma, Melanoma and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Melanoma and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Glioma & glioblastoma, Melanoma and the tag ctgov-sponsor.
- CompanyAura Biosciences
Shares Melanoma and the tag ctgov-sponsor.